The abstract is read at the publisher; the summary is JClub's.
Biologics are linked to lower severe asthma exacerbation rates in a real-world CHRONICLE cohort, with an incidence rate ratio of 0.43 (95% CI 0.39–0.48) across 480 patients.
- Why it matters: Regulatory eligibility criteria can exclude patients from biologic RCTs, but how these criteria shape observed effectiveness and effect modification in real-world severe asthma is unclear.
- What they did: CHRONICLE followed adults with severe asthma in the United States (≥18 years) and compared biologic-exposed versus unexposed periods using a self-controlled case-series, alongside a pooled meta-analysis of six RCTs.
- The result: Effect modification was linked to smoking history (0.50, 0.38–0.66), exacerbation history (0.49, 0.36–0.65), exhaled nitric oxide fraction (0.63, 0.42–0.92), and blood eosinophil count (0.65, 0.51–0.82), while COPD, bronchiectasis, and forced expiratory volume in 1 s criteria showed no significant differences.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.